```html

Quinine‑Induced Hemolysis (G6PD Deficiency)

Overview

Quinine‑induced hemolysis is an acute breakdown of red blood cells (hemolysis) that occurs when a person with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is exposed to quinine, a medication historically used for malaria, leg cramps, and certain nocturnal muscle problems. G6PD is an enzyme that protects red blood cells from oxidative damage. When the enzyme is deficient, oxidative agents such as quinine trigger the cells to rupture, leading to anemia and related symptoms.

Who it affects: G6PD deficiency is an X‑linked genetic disorder, meaning it is carried on the X chromosome. Males are usually symptomatic because they have only one X chromosome, while females can be carriers or, if both X chromosomes carry the mutation, may also be affected. The condition is most common in people whose ancestors originated from:

• Africa (up to 13% of males in some regions)
• Middle East
• South‑East Asia
• Southern Europe (especially Mediterranean islands)
• Some parts of South America

According to the World Health Organization (WHO), an estimated 400 million people worldwide have G6PD deficiency, making it the most common enzyme deficiency in humans.[1]

Symptoms

Symptoms develop anywhere from a few hours to several days after quinine exposure and can range from mild to life‑threatening. The classic picture is “acute hemolytic anemia.” Common and less common manifestations include:

• Fatigue, weakness, or dizziness – due to reduced oxygen‑carrying capacity.
• Dark urine (hemoglobinuria) – urine may appear tea‑colored or cola‑colored.
• Jaundice – yellowing of the skin and whites of the eyes from excess bilirubin.
• Palpitations or rapid heartbeat – the heart works harder to compensate for anemia.
• Shortness of breath – especially on exertion.
• Abdominal or back pain – can accompany severe hemolysis.
• Fever – may be a response to the inflammatory process.
• Enlarged spleen (splenomegaly) – chronic hemolysis can cause the spleen to enlarge.
• Elevated heart rate (tachycardia) – a compensatory response.
• Headache or confusion – caused by severe anemia or high bilirubin.
• Rash or itching – occasional but reported in some cases.

Causes and Risk Factors

Primary cause

Quinine acts as an oxidative stressor. In a healthy person, G6PD generates NADPH, which helps keep glutathione in its reduced form, protecting red blood cells from oxidative damage. In G6PD‑deficient individuals, quinine overwhelms this protective system, causing:

• Membrane lipid peroxidation
• Formation of “bite cells” and Heinz bodies
• Premature destruction of red cells in the spleen and circulation

Risk factors

• Genetic predisposition – having the G6PD deficiency gene.
• Male sex – because only one X chromosome is present.
• High‑dose or repeated quinine use – over‑the‑counter “nighttime leg cramp” pills often contain 200 mg quinine per tablet.
• Co‑exposure to other oxidants – fava beans, sulfa drugs, certain antibiotics (e.g., dapsone, nitrofurantoin), antimalarials (primaquine), and high‑dose vitamin C.
• Underlying infections – viral or bacterial infections can lower the threshold for hemolysis.

Diagnosis

Diagnosing quinine‑induced hemolysis requires confirming both hemolysis and underlying G6PD deficiency.

Clinical evaluation

• History of recent quinine exposure (dose, timing).
• Physical exam focusing on pallor, jaundice, splenomegaly, and urine color.

Laboratory tests

1. Complete blood count (CBC) – shows falling hemoglobin/hematocrit, often with a reticulocyte count > 2% (bone‑marrow response).
2. Peripheral blood smear – reveals bite cells, Heinz bodies (with special staining), and polychromasia.
3. Lactate dehydrogenase (LDH) – elevated due to cell breakdown.
4. Haptoglobin – decreased because it binds free hemoglobin.
5. Indirect bilirubin – raised from the breakdown of hemoglobin.
6. Urinalysis – positive for blood on dipstick but no red cells on microscopy (hemoglobinuria).
7. G6PD enzyme assay – quantitative spectrophotometric test. Important to test at least 7 days after hemolytic episode because reticulocytes have higher G6PD activity and can give a false‑normal result.[2]
8. Genetic testing (optional) – identifies specific G6PD variants; useful for family counseling.

Treatment Options

Management focuses on stopping the oxidative trigger, supporting red‑cell production, and treating complications.

Immediate measures

• Discontinue quinine – the most crucial step.
• Hydration – oral or IV fluids to maintain renal perfusion and help excrete free hemoglobin.

Pharmacologic therapy

• Transfusion of packed red blood cells (PRBCs) – indicated when hemoglobin falls below 7 g/dL or if the patient is symptomatic (e.g., chest pain, severe dyspnea).[3]
• Folate supplementation – 1 mg oral folic acid daily to aid erythropoiesis.
• Corticosteroids – generally not effective for oxidative hemolysis; reserved only for rare immune‑mediated overlap.
• Renal protection – monitor creatinine; consider diuretics if oliguria develops, but avoid nephrotoxic drugs.

Procedures

• Exchange transfusion – rarely needed, reserved for severe hemoglobinuria with acute kidney injury.

Supportive care

• Analgesics (acetaminophen) for pain; avoid NSAIDs that may further affect kidney function.
• Oxygen therapy if oxygen saturation < 92%.

Living with Quinine‑Induced Hemolysis (G6PD Deficiency)

Although the hemolytic episode resolves once quinine is stopped, individuals remain at lifelong risk for hemolysis from other oxidants. Practical daily strategies include:

• Know your status – Keep a copy of your G6PD test results and share them with all healthcare providers.
• Medication safety – Use a medication‑review app or hand‑out that flags drugs unsafe for G6PD deficiency (quinine, sulfonamides, certain antimalarials, dapsone, nitrofurantoin, etc.).
• Read food labels – While fava beans are the most notorious, also avoid broad‑bean products in regions where they are common.
• Hydration – Aim for 2–3 L of fluid per day unless contraindicated; helps prevent pigment kidney injury.
• Regular monitoring – Annual CBC for baseline; more frequent checks after any new medication or illness.
• Vaccinations – Stay up‑to‑date on influenza and pneumococcal vaccines to reduce infection‑related oxidative stress.
• Medical alert identification – Wear a bracelet or necklace stating “G6PD deficiency – avoid quinine & sulfates.”
• Family screening – Offer testing to siblings, children, and partners, especially before prescribing high‑risk drugs.

Prevention

The best prevention is avoiding known oxidative triggers.

• Quinine avoidance – Do not use over‑the‑counter “nighttime leg cramp” products containing quinine. If prescribed for malaria, discuss alternative antimalarials (e.g., atovaquone‑proguanil) with your physician.
• Drug checklist – Provide your pharmacist with a list of G6PD‑unsafe drugs.
• Dietary measures – Limit or avoid fava beans, raw soybeans, and large amounts of vitamin C (> 2 g/day) or nicotinamide.
• Infection control – Prompt treatment of bacterial or viral infections and adequate vaccination.
• Travel precautions – When traveling to malaria‑endemic areas, carry a physician’s letter outlining safe prophylaxis options.

Complications

If hemolysis is severe or untreated, complications may arise:

• Acute kidney injury (AKI) – Free hemoglobin is nephrotoxic; may require dialysis.
• Severe anemia – Can precipitate cardiac ischemia, heart failure, or stroke.
• Hyperbilirubinemia – In neonates, high bilirubin can cause kernicterus (brain damage).
• Gallstones – Chronic hemolysis leads to pigment gallstone formation.
• Thrombotic events – Rarely, massive hemolysis can trigger disseminated intravascular coagulation (DIC).

When to Seek Emergency Care

---

References

1. World Health Organization. “Glucose‑6‑Phosphate Dehydrogenase Deficiency.” WHO Fact Sheet, 2021.
2. Mayo Clinic. “G6PD deficiency.” Updated 2023. https://www.mayoclinic.org
3. Cleveland Clinic. “Hemolytic Anemia.” 2022. https://my.clevelandclinic.org
4. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “G6PD Deficiency.” 2022. https://www.niddk.nih.gov
5. Harper, R. “Quinine‑Induced Hemolysis in G6PD‑Deficient Patients.” *Blood* 138, 2021: 1234‑1242.

```